Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors
© 2022 John Wiley & Sons Ltd..
BACKGROUND AND AIMS: Dual blockade of BRAF and MEK kinases is a standard of care for metastatic V600E/K BRAF mutant melanoma. This study reports the first systematic description of colitis due to BRAF and MEK inhibitors.
METHODS: We studied consecutive patients with melanoma, treated with BRAF and MEK inhibitors, who had colitis requiring hospitalisation. Electronic files were studied; endoscopic biopsies and colectomy specimens were read centrally.
RESULTS: Between January 2021 and March 2022, nine women and one man, aged 50-90 years, were studied. Nine patients received encorafenib and binimetinib; one patient received dabrafenib and trametinib. The main symptoms were diarrhoea, haematochezia, abdominal pain and intestinal obstruction. Blood tests showed anaemia, increased CRP and low serum albumin levels in most patients. All patients had ulcerations of the right colon with (2/10) or without (8/10) stenosis of the ileocecal valve, and 4/10 patients also had ulcerations distal to the right colon. Histopathological findings were suggestive of ischaemia and mild inflammation. Nine of the 10 patients discontinued BRAF/MEK inhibitors. Drugs were reintroduced in four patients, three of whom had a severe relapse of diarrhoea. Two patients required surgery and underwent intestinal resection. One patient died of enterocolitis.
CONCLUSION: BRAF/MEK inhibitors can induce severe colitis characterised by ulcerations of the right colon.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(7):808-809. - PMID 36913503 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 57(2023), 7 vom: 17. Apr., Seite 792-799 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carbonnel, Franck [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF/MEK inhibitor |
|---|
| Anmerkungen: |
Date Completed 17.03.2023 Date Revised 09.05.2023 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(7):808-809. - PMID 36913503 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.17352 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350894817 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350894817 | ||
| 003 | DE-627 | ||
| 005 | 20231226050028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.17352 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350894817 | ||
| 035 | |a (NLM)36578099 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carbonnel, Franck |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2023 | ||
| 500 | |a Date Revised 09.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(7):808-809. - PMID 36913503 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND AND AIMS: Dual blockade of BRAF and MEK kinases is a standard of care for metastatic V600E/K BRAF mutant melanoma. This study reports the first systematic description of colitis due to BRAF and MEK inhibitors | ||
| 520 | |a METHODS: We studied consecutive patients with melanoma, treated with BRAF and MEK inhibitors, who had colitis requiring hospitalisation. Electronic files were studied; endoscopic biopsies and colectomy specimens were read centrally | ||
| 520 | |a RESULTS: Between January 2021 and March 2022, nine women and one man, aged 50-90 years, were studied. Nine patients received encorafenib and binimetinib; one patient received dabrafenib and trametinib. The main symptoms were diarrhoea, haematochezia, abdominal pain and intestinal obstruction. Blood tests showed anaemia, increased CRP and low serum albumin levels in most patients. All patients had ulcerations of the right colon with (2/10) or without (8/10) stenosis of the ileocecal valve, and 4/10 patients also had ulcerations distal to the right colon. Histopathological findings were suggestive of ischaemia and mild inflammation. Nine of the 10 patients discontinued BRAF/MEK inhibitors. Drugs were reintroduced in four patients, three of whom had a severe relapse of diarrhoea. Two patients required surgery and underwent intestinal resection. One patient died of enterocolitis | ||
| 520 | |a CONCLUSION: BRAF/MEK inhibitors can induce severe colitis characterised by ulcerations of the right colon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRAF/MEK inhibitor | |
| 650 | 4 | |a colitis | |
| 650 | 4 | |a melanoma | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Mitogen-Activated Protein Kinase Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.12.2 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Routier, Emilie |e verfasserin |4 aut | |
| 700 | 1 | |a Lazure, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Mussini, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Bellanger, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Merklen, Carine |e verfasserin |4 aut | |
| 700 | 1 | |a Bejou, Bakhtiar |e verfasserin |4 aut | |
| 700 | 1 | |a Buisson, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Amiot, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Caroline |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 57(2023), 7 vom: 17. Apr., Seite 792-799 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2023 |g number:7 |g day:17 |g month:04 |g pages:792-799 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.17352 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2023 |e 7 |b 17 |c 04 |h 792-799 | ||